Response to Comments: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease

The provided file is a Noridian 'Response to Provider Recommendations' and does not include explicit, actionable coverage criteria for genetic testing for BCR-ABL negative myeloproliferative disease. Acquire the complete policy/policy changes to extract indications, exclusions, required documentation, and any frequency limits; manual review is required.

"The provided document is a Noridian response to provider comments (comment period ending 08/10/2015) and does not contain the full coverage criteria for genetic testing for BCR-ABL negative myelopr..."

Sign up to see full coverage criteria, indications, and limitations.